IRVING, Texas --(BUSINESS WIRE)--Oct. 31, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide third quarter financial results on Tuesday, November 8,
IRVING, Texas --(BUSINESS WIRE)--Oct. 10, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time
Biote Method to be available in IMAC outpatient medical clinics IRVING, Texas --(BUSINESS WIRE)--Sep. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has
Company will resume trading under its existing symbols “BTMD” and “BTMDW” IRVING, Texas --(BUSINESS WIRE)--Aug. 25, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that The Nasdaq
IRVING, Texas --(BUSINESS WIRE)--Aug. 24, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr.
IRVING, Texas --(BUSINESS WIRE)--Aug. 15, 2022-- Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Second Quarter 2022 Financial Results,” issued on August 9, 2022 .
Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance * Revised Dial -in Information for the Conference Call* IRVING, Texas --(BUSINESS WIRE)--Aug. 9, 2022-- Biote , a high growth, differentiated medical practice-building business
IRVING, Texas --(BUSINESS WIRE)--Jul. 20, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022 , after market close on
Innovative physician leader brings over 20 years of experience to Biote’s executive team IRVING, Texas --(BUSINESS WIRE)--Jun. 16, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, today announced
IRVING, Texas --(BUSINESS WIRE)--Jun. 6, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, differentiated medical practice-building business within the hormone optimization space, today announces that Terry Weber , Biote’s Chief Executive Officer, is scheduled to present
